Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

Illinois Compiled Statutes

 ILCS Listing   Public Acts  Search   Guide   Disclaimer

Information maintained by the Legislative Reference Bureau
Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process. Recent laws may not yet be included in the ILCS database, but they are found on this site as Public Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the Guide.

Because the statute database is maintained primarily for legislative drafting purposes, statutory changes are sometimes included in the statute database before they take effect. If the source note at the end of a Section of the statutes includes a Public Act that has not yet taken effect, the version of the law that is currently in effect may have already been removed from the database and you should refer to that Public Act to see the changes made to the current law.

410 ILCS 416/20

    (410 ILCS 416/20)
    Sec. 20. Requirements; notice.
    (a) The program:
        (1) must collaborate with physicians, health care
    
providers, and clinical trial sponsors to notify a prospective subject about the program when:
            (A) the prospective subject consents to a
        
clinical trial; or
            (B) funding is available to provide the program
        
for the clinical trial in which the prospective subject participates;
        (2) must reimburse subjects based on financial need,
    
which may include reimbursement to subjects whose income is at or below 700% of the federal poverty level;
        (3) must provide reimbursement for ancillary costs,
    
including costs described under Section 15, to eliminate the financial barriers to enrollment in a clinical trial;
        (4) may provide reimbursement for reasonable
    
ancillary costs, including costs described under Section 15, to one family member, friend, or other person who attends a clinical trial to support a subject; and
        (5) must comply with applicable federal and State
    
laws.
    (b) The independent third-party organization administering the program shall provide written notice to prospective subjects of the requirements described under subsection (a).
(Source: P.A. 103-227, eff. 6-30-23.)